Treatment of chronic autoimmune urticaria with omalizumab

Journal of Allergy and Clinical Immunology

Volumn 122, Issue 3, 2008, Pages 569-573

  Kaplan, Allen P ^a,b   Joseph, Kusumam ^b   Maykut, Robert J ^c   Geba, Gregory P ^c   Zeldin, Robert K ^c  

^a National Allergy   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

angioedema; antihistamines; autoantibody; Chronic urticaria; IgE receptor; omalizumab

Indexed keywords

HISTAMINE; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO;

ADULT; AGED; ARTICLE; BASOPHIL; CHRONIC URTICARIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTAMINE RELEASE; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SKIN TEST;

ADULT; ANTI-ALLERGIC AGENTS; ANTIBODIES, MONOCLONAL; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BASOPHILS; FEMALE; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; HYDROXYZINE; IMMUNOGLOBULIN E; MALE; MAST CELLS; MIDDLE AGED; RECEPTORS, IGE; URTICARIA;

EID: 50649084564     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2008.07.006     Document Type: Article

References (28)

1. Hide M., Francis D., Grattan C., Hakimi J., Kochan J.P., and Greaves M.W. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 328 (1993) 1599-1604
2. Kikuchi Y., and Kaplan A. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 107 (2001) 1056-1062
3. Niimi N., Francis D., Kermani F., O'Donnell B.F., Hide M., Kobza-Black A., et al. Dermal mast cell activation by autoantibodies against the high affinity IgE receptor in chronic urticaria. J Invest Dermatol 106 (1996) 1001-1006
4. Soundararajan S., Kikuchi Y., Joseph K., and Kaplan A.P. Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria. J Allergy Clin Immunol 115 (2005) 815-821
5. Kikuchi Y., and Kaplan A. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 109 (2002) 114-118
6. Hugli T., and Muller-Eberhard H. Anaphylatoxins: C3a and C5a. Adv Immunol 26 (1978) 1-53
7. Elias J., Boss E., and Kaplan A. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-lymphocytes, monocytes, and mast cells. J Allergy Clin Immunol 78 (1986) 914-918
8. Sabroe R., Poon E., Orchard G., Lane D., Francis D.M., Barr R.M., et al. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Allergy Clin Immunol 103 (1999) 484-493
9. Leznoff A., Josse R., Denburg J., and Dolovich J. Association of chronic urticaria and angioedema with thyroid autoim. Arch Dermatol 119 (1983) 636-640
10. Leznoff A., and Sussman G. Syndrome of idiopathic chronic urticaria and angioedema with thyroid autoimmunity: a study of 90 patients. J Allergy Clin Immunol 84 (1989) 66-71
11. Kikuchi Y., Fann T., and Kaplan A. Antithyroid antibodies in chronic urticaria and angioedema. J Allergy Clin Immunol 112 (2003) 218
12. Kaplan A. Chronic urticaria and angioedema. N Engl J Med 346 (2002) 175-179
13. MacGlashan Jr. D., Xia H.Z., Schwartz L.B., and Gong J. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukocyte Biol 70 (2001) 207-218
14. Beck L.A., Marcotte G.V., MacGlashan D., Togias A., and Saini S. Omalizumab-induced reductions in mast cell Fcepsilon RI expression and function. J Allergy Clin Immunol 1050 (2005) 73-88
15. Grattan C., Boon A., Eady R., and Winkelmann R.K. The pathology of the autologous serum skin test response in chronic urticaria resembles IgE-mediated late-phase reactions. Int Arch Allergy Immunol 93 (1990) 198-204
16. Finlay A.Y., and Khan G.K. Dermatology Life Quality Index (DLQI): a simple practical measure for routine use. Clin Exptl Dermatol 19 (1994) 210-216
17. Poon E., Seed P.T., Greaves M.W., and Kobza-Black A. The extent and nature of disability in different urticarial conditions. Br J Dermatol 140 (1999) 667-671
18. Baiardini I., Giardini A., Pasquali M., Dignetti P., Guerra L., Specchia C., et al. Quality of life and patients' satisfaction in chronic urticaria and respiratory allergy. Allergy 58 (2003) 621-623
19. Kaplan A.P. Urticaria and angioedema. In: Wolff K., Goldsmith L.A., Katz S.I., Gilchrist B.A., Paller A.S., and Leffell D.J. (Eds). Fitzpatrick's dermatology in general medicine. 7th ed. (2007), McGraw-Hill Publishing, New York 330-343
20. Toubi E., Blant A., Kessel A., and Golan T.D. Low-dose cyclosporin A in the treatment of severe chronic idiopathic urticaria. Allergy 52 (1997) 312-316
21. Grattan C., O'Donnell B., Francis D., Niimi N., Barlow R.J., Seed P.T., et al. Randomized double-blind study of cyclosporin in chronic "idiopathic" urticaria. Br J Dermatol 143 (2000) 365-372
22. Gruber B.L., Baeza M.L., Marchese M.J., and Kaplan A.P. Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes. J Invest Dermatol 90 (1988) 213-217
23. Sabroe R., Fiebiger E., Francis D., Maurer D., Seed P.T., Grattan C.E., et al. Classification of anti-FcepsilonRI and anti-IgE autoantibodies in chronic idiopathic urticaria and correlation with disease severity. J Allergy Clin Immunol 40 (2002) 492-499
24. Segal D.M., Taurog J.D., and Metzger H. Dimeric immunoglobulin E serves as a unit signal for mast cell degranulation. Proc Natl Acad Sci U S A 74 (1977) 2993-2997
25. Spector S., and Tan R. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 99 (2007) 190-193
26. Kaplan A., and Joseph K. Basophil secretion in chronic urticaria: autoantibody-dependent or not?. J Allergy Clin Immunol 120 (2007) 729-730
27. Sabroe R., Grattan C., Francis D., Barr R.M., Kobza Black A., and Greaves M.W. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 140 (1999) 446-452
28. Gomez G., Jogie-Brahim S., Shima M., and Schwartz L.B. Omalizumab reverses the phenotypic and functional effects of IgE-enhanced Fc epsilonRI on human skin mast cells. J Immunol 179 (2007) 1353-1361